Your browser is no longer supported. Please, upgrade your browser.
Rigel Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-0.17 Insider Own0.31% Shs Outstand168.93M Perf Week5.51%
Market Cap725.74M Forward P/E- EPS next Y-0.20 Insider Trans0.00% Shs Float168.46M Perf Month18.27%
Income-27.70M PEG- EPS next Q-0.11 Inst Own84.90% Short Float11.49% Perf Quarter38.42%
Sales105.60M P/S6.87 EPS this Y9.00% Inst Trans-0.31% Short Ratio5.24 Perf Half Y76.43%
Book/sh0.30 P/B14.35 EPS next Y-17.60% ROA-20.10% Target Price- Perf Year99.31%
Cash/sh0.43 P/C9.97 EPS next 5Y- ROE-45.00% 52W Range1.23 - 5.50 Perf YTD23.00%
Dividend- P/FCF- EPS past 5Y17.40% ROI-108.60% 52W High-21.73% Beta1.45
Dividend %- Quick Ratio2.90 Sales past 5Y48.40% Gross Margin99.30% 52W Low250.00% ATR0.35
Employees163 Current Ratio2.90 Sales Q/Q-12.00% Oper. Margin-26.00% RSI (14)51.74 Volatility6.56% 7.77%
OptionableYes Debt/Eq0.39 EPS Q/Q-22.40% Profit Margin-26.20% Rel Volume1.58 Prev Close4.47
ShortableYes LT Debt/Eq0.39 EarningsMar 02 AMC Payout- Avg Volume3.69M Price4.30
Recom1.70 SMA20-2.71% SMA509.01% SMA20053.17% Volume5,838,777 Change-3.69%
Nov-09-20Downgrade JP Morgan Overweight → Neutral
Nov-15-19Resumed Cantor Fitzgerald Overweight $7 → $5
Sep-26-19Resumed JP Morgan Overweight $7
Mar-01-19Reiterated Cantor Fitzgerald Overweight $9 → $7
Aug-27-18Initiated Citigroup Buy $8.50
May-02-18Reiterated Cantor Fitzgerald Overweight $6 → $9
Dec-21-17Resumed Piper Jaffray Overweight $6
Dec-15-17Initiated Cantor Fitzgerald Overweight $6
Nov-06-17Resumed H.C. Wainwright Buy $7
Mar-09-17Reiterated H.C. Wainwright Buy $6 → $5
Aug-31-16Reiterated H.C. Wainwright Buy $6 → $7
Aug-30-16Reiterated Piper Jaffray Overweight $10 → $11
Jul-13-16Initiated H.C. Wainwright Buy $6
Jun-13-16Initiated Piper Jaffray Overweight
Apr-22-16Upgrade JP Morgan Neutral → Overweight
Apr-08-13Reiterated Stifel Buy $11 → $7
Nov-29-12Initiated UBS Neutral $9
Nov-06-12Reiterated Oppenheimer Outperform $12 → $15
Mar-26-12Initiated Canaccord Genuity Hold $8
Dec-10-10Downgrade MP Advisors Outperform → Market Perform
Mar-02-21 04:01PM  
Feb-23-21 07:30AM  
Feb-21-21 07:21AM  
Feb-18-21 12:40PM  
Jan-29-21 02:45PM  
Jan-22-21 01:36PM  
Jan-11-21 07:30AM  
Jan-07-21 07:30AM  
Dec-21-20 08:55AM  
Dec-19-20 10:40PM  
Dec-15-20 02:51AM  
Dec-04-20 07:30AM  
Nov-23-20 07:30AM  
Nov-17-20 07:30AM  
Nov-10-20 07:30AM  
Nov-09-20 08:07AM  
Nov-06-20 03:01PM  
Nov-05-20 06:35PM  
Oct-29-20 07:30AM  
Oct-14-20 01:47PM  
Oct-09-20 07:30AM  
Oct-02-20 12:26PM  
Sep-18-20 10:52AM  
Sep-17-20 09:46AM  
Sep-09-20 07:30AM  
Sep-02-20 07:30AM  
Aug-27-20 01:09PM  
Aug-21-20 07:30AM  
Aug-05-20 11:48AM  
Aug-04-20 06:35PM  
Jul-28-20 12:33PM  
Jul-27-20 04:04PM  
Jul-14-20 05:03PM  
Jul-09-20 08:19AM  
Jun-27-20 09:29PM  
Jun-26-20 08:48AM  
Jun-17-20 07:30AM  
Jun-12-20 10:03PM  
Jun-11-20 07:30AM  
Jun-03-20 07:30AM  
May-26-20 07:30AM  
May-08-20 11:03AM  
May-06-20 12:31PM  
May-05-20 06:15PM  
May-01-20 07:30AM  
Apr-28-20 12:33PM  
Apr-27-20 07:30AM  
Apr-11-20 10:20AM  
Mar-24-20 02:19AM  
Mar-12-20 11:02AM  
Mar-03-20 12:56PM  
Feb-27-20 06:05PM  
Feb-20-20 12:31PM  
Feb-11-20 12:14PM  
Jan-13-20 05:03PM  
Jan-10-20 12:54PM  
Jan-09-20 08:40AM  
Dec-18-19 07:23AM  
Dec-17-19 05:00PM  
Dec-11-19 02:44PM  
Nov-19-19 08:40AM  
Nov-18-19 05:34PM  
Nov-15-19 07:30AM  
Nov-13-19 07:30AM  
Nov-08-19 08:00AM  
Nov-07-19 07:30AM  
Nov-06-19 02:32PM  
Nov-05-19 06:05PM  
Oct-29-19 10:32AM  
Oct-23-19 07:30AM  
Oct-22-19 01:04PM  
Rigel Pharmaceuticals, Inc., a biotechnology company, engages in the discovery and development of small molecule drugs for the treatment of immune and hematologic disorders, cancer, and rare diseases. The company offers Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia. It also develops Fostamatinib that is in phase III clinical trials for warm autoimmune hemolytic anemia; R835, an oral interleukin receptor associated kinase 1/4 inhibitor, which is in phase I clinical trials for autoimmune and inflammatory diseases; and R552, a receptor-interacting protein kinase Inhibitor that is in phase I clinical trials for autoimmune and inflammatory diseases. The company has research and license agreements with Aclaris Therapeutics International Limited for the development and commercialization of janus kinase (JAK) inhibitors for the treatment of alopecia areata and other dermatological conditions; AstraZeneca AB for the development and commercialization of R256, an inhaled JAK inhibitor; BerGenBio AS for the development and commercialization of AXL inhibitors in oncology; and Daiichi Sankyo to develop murine double minute 2 inhibitors for solid and hematological malignancies, as well as license and supply agreement with Kissei Pharmaceutical Co., Ltd. to develop and commercialize Fostamatinib. It also has a license agreement and strategic collaboration with Eli Lilly and Company to co-develop and commercialize R552 for various indications, including autoimmune and inflammatory diseases. Tavalisse. Rigel Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in South San Francisco, California.